| Serial Number | 79213106 |
| Word Mark | OC |
| Filing Date | Monday, February 6, 2017 |
| Status | 739 - Section 71 & 15 - ACCEPTED AND ACKNOWLEDGED |
| Status Date | Friday, June 13, 2025 |
| Registration Number | 5466730 |
| Registration Date | Tuesday, May 15, 2018 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, February 27, 2018 |
| Description of Mark | The mark consists of two side-by-side, touching circles, in which the circle on the right has two breaks. The circle on the left is light blue on the left, blue in the middle, and green on the right. The broken circle on the right is three quarters green and the separated one quarter portion is light gray. |
| Goods and Services | Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all ] for use in human [ and veterinary ] medicine; Chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Prescription and non-prescription ] medicines, [ namely, pills, tablets, capsules, caplets, liquid drops, sachets, and ] pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; ] Biological preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; ] Biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Diagnostic preparations for medical purposes; ] Medicines for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; ] Biological reagents for medical use; Medicinal preparations based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; [ Medicinal preparations based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; Products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, natural killer cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ Gene therapy products, namely, genetically engineered tissues for transplant purposes; Medicaments, namely, cells and tissues that have been subjected to extensive manipulation, to help assist with the regeneration of ligament and tendon fibers; ] Preparations for personalized medicine made of [ autologous cells or proteins or ] nucleic acids derived from individual genomic sequences; [ Preparations made up of cells for medical or clinical use; ] Preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; Preparations made up of tissues, namely, biological tissue cultures for medical purposes; Vaccines; Recombinant proteins supplements; Therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ] |
| Indication of Colors claimed | The color(s) light blue, blue, green and light grey is/are claimed as a feature of the mark. |
| Goods and Services | Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; Research and development in the pharmaceutical and biotechnology fields; Research and development in the field of micro-organisms and cells; Research and development in the field of biochemistry; Scientific research and development in the field of biology; Research and development in the field of diagnostic preparations; Services of medical laboratories; Compiling medical information and data for research and development purposes in the medical and veterinary fields; Scientific and technological services, namely, scientific research and technical writing; Scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes in the field of biology |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 28, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 28, 2017 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ANEMOCYTE S.R.L. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | GERENZANO (VA) I-21040 IT |
| Party Name | ANEMOCYTE S.R.L. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IT |
| Party Name | ANEMOCYTE S.R.L. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IT |
| Event Date | Event Description |
| Thursday, July 27, 2017 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Thursday, July 27, 2017 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, July 28, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, July 28, 2017 | ASSIGNED TO EXAMINER |
| Monday, July 31, 2017 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 1, 2017 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, August 1, 2017 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, August 3, 2017 | REFUSAL PROCESSED BY MPU |
| Thursday, August 3, 2017 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, October 20, 2017 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, August 18, 2017 | REFUSAL PROCESSED BY IB |
| Friday, October 20, 2017 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, January 22, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, January 22, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 25, 2018 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, January 25, 2018 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, January 25, 2018 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, January 25, 2018 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, February 7, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, January 3, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, January 18, 2018 | ASSIGNED TO LIE |
| Thursday, January 25, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, February 27, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, August 15, 2018 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, August 24, 2018 | FINAL DISPOSITION NOTICE SENT TO IB |
| Saturday, September 15, 2018 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Monday, October 24, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, February 22, 2018 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Tuesday, February 27, 2018 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 15, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Friday, August 24, 2018 | FINAL DISPOSITION PROCESSED |
| Friday, April 9, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, October 24, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, October 24, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Monday, October 24, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, October 24, 2022 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Monday, October 24, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, October 24, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, May 14, 2024 | TEAS SECTION 71 & 15 RECEIVED |
| Monday, May 15, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Monday, December 16, 2024 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Wednesday, December 18, 2024 | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 |
| Thursday, June 5, 2025 | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED |
| Friday, June 13, 2025 | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. |
| Monday, August 18, 2025 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Friday, June 13, 2025 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED |